- Home
- XAIR vs EQ Comparison
XAIR vs EQ Comparison
Compare XAIR & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XAIR
- EQ
- Stock Information
- Founded
- XAIR 2011
- EQ 2017
- Country
- XAIR United States
- EQ United States
- Employees
- XAIR N/A
- EQ N/A
- Industry
- XAIR Medical/Dental Instruments
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- XAIR Health Care
- EQ Health Care
- Exchange
- XAIR Nasdaq
- EQ Nasdaq
- Market Cap
- XAIR 34.7M
- EQ 39.0M
- IPO Year
- XAIR N/A
- EQ 2018
- Fundamental
- Price
- XAIR $0.50
- EQ $0.71
- Analyst Decision
- XAIR Strong Buy
- EQ Buy
- Analyst Count
- XAIR 4
- EQ 2
- Target Price
- XAIR $3.67
- EQ $5.00
- AVG Volume (30 Days)
- XAIR 636.5K
- EQ 311.1K
- Earning Date
- XAIR 11-11-2024
- EQ 11-13-2024
- Dividend Yield
- XAIR N/A
- EQ N/A
- EPS Growth
- XAIR N/A
- EQ N/A
- EPS
- XAIR N/A
- EQ N/A
- Revenue
- XAIR $2,342,000.00
- EQ $45,914,000.00
- Revenue This Year
- XAIR $640.47
- EQ N/A
- Revenue Next Year
- XAIR $286.81
- EQ N/A
- P/E Ratio
- XAIR N/A
- EQ N/A
- Revenue Growth
- XAIR 685.91
- EQ 7.70
- 52 Week Low
- XAIR $0.30
- EQ $0.48
- 52 Week High
- XAIR $2.36
- EQ $3.25
- Technical
- Relative Strength Index (RSI)
- XAIR 56.04
- EQ 39.09
- Support Level
- XAIR $0.42
- EQ $0.68
- Resistance Level
- XAIR $0.56
- EQ $0.89
- Average True Range (ATR)
- XAIR 0.07
- EQ 0.11
- MACD
- XAIR 0.00
- EQ -0.03
- Stochastic Oscillator
- XAIR 47.32
- EQ 5.49
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.